On 15 February 2019, the German competent authority, in accordance with Article 54a(4) of Directive 2001/83/EC and Article 46(2) of Delegated Regulation (EU) 2016/161, informed the Commission by email that they do not deem the medicinal product subject to prescription Zinc-D-gluconate to be at risk of falsification according to the criteria set out in Article 54a(2), point b, of Directive 2001/83/EC. The German competent authority considered that Zinc-D-gluconate should therefore be exempted from the requirement to bear the safety features referred to in Article 54, point (o), of Directive 2001/83/EC.
Recital 2, Decision_act (EU) 2021/1125
In forcesince 8 Jul 2021